GlassScriptPhysician profile
Basharat H Muneer
NPI 1508015181
$1,840.14
in general payments reported to CMS, 2019-2025
21 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $139 · 2021: $234 · 2022: $164 · 2023: $208 · 2024: $439 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $458.41 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $273.50 | 2023-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Novartis Pharmaceuticals Corporation | $205.93 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $155.31 | 2019-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $118.18 | 2022-2025 | Verquvo |
| Pfizer INC. | $110.26 | 2019 | |
| Abiomed | $87.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $73.71 | 2019-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $69.47 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $57.65 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $55.30 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.87 | 2019 | |
| Medtronic Vascular, INC. | $31.08 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $25.68 | 2024 | |
| Biotronik INC. | $21.35 | 2024 | Recross, Trapit, Nhancer Rx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $19.52 | 2023 | |
| Lantheus Medical Imaging, INC. | $18.03 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.89 | 2023 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.10 | 2024 | Lifevest |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basharat Muneer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.